JanOne
A US firm that draws private-sector resources into the urgent fight against opioids.
JanOne is seeking innovative treatments—focusing on developing revolutionary, non-addictive drugs that kill pain, not people.
In November 2019, JanOne announced a licensing agreement for TV1001SR, a treatment for peripheral artery disease.
The agreement gives JanOne a worldwide, exclusive license for TV1001SR along with a portfolio of 30 patents and other intellectual property relating to the sustained release of sodium nitrite.
Latest JanOne News & Features
25 November 2019
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze